

# Cancer Is A Disorder of Cell Death: **Biologic Impact of Targeted Therapies**


Michael T. Lotze, MD

Vice Chair and Chief, Translational Research

Departments of Surgery and Bioengineering

University of Pittsburgh Cancer Institute

Effect of tumour cells killed by x-rays upon the growth of admixed viable cells.  
 LÁSZLÓ [Laci] RÉVÉSZ (1926-2000) [Nature. 1956 Dec 22;178(4547):1391-2.  
 Karolinska



Effect of cells lethally damaged by 15,000 R  $\gamma$ -irradiation on growth of viable cells + a spontaneous C3H mammary carcinoma. REVESZ L. Effect of lethally damaged tumor cells upon the development of admixed viable cells. J Natl Cancer Inst. 1958 Jun;20(6):1157-86.


# Stimulation Exerted by Dead Cells

- Specific stimulation by homologous cell products
- A 'feeder effect' in which the dead cells release essential nutrients
- Stimulation through provoking an inflammatory response and/or vascularization from the side of the host

# TLRs, NLRs, and RLRs

Review


## TIR, CARD and PYRIN: three domains for an antimicrobial triad ? Cancer



# Death Used to be Simpler

## Apoptosis [I], Autophagy [II] and Necrosis [III]

---



# Cell Death

## Different types of "Cell Death"

	NECROSIS	APOPTOSIS	ANOIKIS	CASPASE- INDEPENDENT APOPTOSIS	AUTOPHAGY	WD	EXCITO- TOXICITY	ERYTHRO- POIESIS	PLT	CORNI- FICATION	LENS
<b>Genetic Program</b>	None	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
<b>Membrane</b>	Lysed	intact PS exposure	intact PS exp.	intact PS exp.	intact PS exposure	intact	intact	intact	intact	intact	
<b>Organelles</b>	Lysed	intact	intact	intact	intact lipid- reassembly	intact	intact	intact	intact	crosslinked lipid- reassembly	
<b>Mitos</b>	Blown	intact	intact					lost		lost	lost
<b>Nucleus</b>		chr.condens. DNA fragm.	chr.cond. DNA frag	chr.cond DNA fragm.	chr.condens. DNA fragm.			lost	lost	lost	lost
<b>Enzymes</b>	None	caspases	caspases	calpains	lysosomal beclin1	VPR	calpains NCX	calpains		TG 1,3,5	TG
<b>Receptors</b>		Death Rec									
<b>Regulators</b>		Bcl family IAP					NO calcium	GATA2		AP1 calcium	
	-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-	-9-	-10-	-11-

Current Model

11 forms of cell death

Classical Model

Type1: Apoptosis  
Type2: Autophagy  
Type3: Necrosis

G. Mollino, P. Nicotera et al., *Cell Death and Differentiation*, 12 (2005)

## REVIEW

## Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

S Fulda and K-M Debatin


University Children's Hospital, Ulm, Germany

• Current cancer therapies, for example, chemotherapy,  $\gamma$ -irradiation, immunotherapy, or suicide gene therapy, primarily exert their antitumor effect by triggering apoptosis in cancer cells

• So far, no clear pattern has emerged between the level of apoptosis or proteins that regulate apoptosis and treatment response in most solid tumors


• Strategies Targeting the Intrinsic Pathway

- Bcl-2 Family Proteins
- Smac/Diablo Agonists
- Irradiation



## Process of Autophagy

- environmental stressors lead to isolation of double membrane-bound structures thought to be derived from the “phagophore”
- membrane structures elongate and mature and MAP-LC3 is recruited to the membrane
- elongated double membranes form autophagosomes and sequester cytosolic proteins and organelles
- sequestration requires ATP and microtubules
- process can be inhibited by blocking ATP production or microtubule assembly
- the autophagosome fuses with the lysosome which proceeds with degradation



# Autophagy and Cancer


- Overexpression of beclin-1 (the yeast homolog of Atg6) induces autophagy in tumor cells and inhibits their tumorigenicity (acts as tumor suppressor). Beclin-1 is regulated by BCL-2
- Other tumor suppressor genes linked to autophagy include PTEN and tensin homologs
- Tamoxifen induces autophagic cell death of breast cancer cells through the oestrogen receptor and occurs through downregulation of AKT

## Therapies that induce autophagy in cancer cells Kondo Y et al., *Nature Reviews*, 5 (2005)

Treatment	Proposed target	Cancer type
Tamoxifen	Oestrogen receptor	Breast cancer
Temozolomide	DNA	Malignant glioma
$\gamma$ -Irradiation	DNA	Breast cancer, prostate cancer, colon cancer, malignant glioma
Sodium butyrate and SAHA	HDAC	Cervical cancer that overexpresses BCL-X <sub>L</sub>
Hyperthermia	Unknown	Malignant glioma
Arsenic trioxide	Multiple targets (for example, mitochondria)	Malignant glioma
Resveratrol	Multiple targets (for example, oestrogen receptor and mitochondria)	Ovarian cancer
Soybean B-group triterpenoid saponins	Unknown	Colon cancer
Rapamycin	mTOR	Malignant glioma

HDAC, histone deacetylase; mTOR, mammalian target of rapamycin; SAHA, suberoylanilide hydroxamic acid.

# Autophagy and Cancer



## Inhibitors of autophagy

Compound	Modification of cellular component	Cancer type
3-MA	PI3K inhibitor. Inhibits the formation of pre-autophagosomal structure	Breast cancer, prostate cancer, colon cancer, malignant glioma and cervical cancer
Bafilomycin A <sub>1</sub>	H <sup>+</sup> -ATPase inhibitor. Blocks the fusion of the autophagosome and lysosome	Breast cancer, prostate cancer, colon cancer, malignant glioma, cervical cancer
HCQ	A lysosomotropic agent. Blocks the fusion of the autophagosome and lysosome	Cervical cancer
Monensin	Proton exchange for potassium or sodium. Blocks the fusion of the autophagosome and lysosome	Cervical cancer
siRNA against ATG5, BECN1, ATG10, ATG12	Blocks translation of these proteins	Cervical cancer

3-MA, 3-methyladenine; HCQ, hydroxychloroquine; PI3K, phosphatidylinositol 3-phosphate kinase; siRNA, small interfering RNA.

- MAP-LC3


(Microtubule Associated Protein Light Chain 3)

Homolog of the yeast Apg8 protein which is essential for formation of autophagosomes. Present as two isoforms (I&II).


LC3-II Localizes to the limiting membranes of autophagosomes after processing.

- Monodansylcadaverine (MDC)

lysomotrophic compound that has been shown to accumulate in autophagosomes (Biederbeck et al., 1995)



# The ArrayScan VTI and High Content Screening (HCS)



# Autophagy in Melanoma





Hoechst 33342

MDC





LC3

MERGE





No tx



PBS  
(-) CaMg




As2O3



# Autophagy in Melanoma


**WM9 undergoes autophagy in response to starvation and arsenic trioxide as measured by an increase in cytoplasmic spot intensity**




**Cells appear to be protected from autophagy in the presence of  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$  cations**

LTR = LysoTracker Red  
MDC = Monodansylcadaverine  
LC3 = MAP LC3

MDC



LC3



# Classes of Molecules That Initiate The Innate Immune Response – Signal 0

---

## Pathogen-associated Molecular Patterns (PAMPs):

Molecules expressed or released by invading microorganisms that are structurally unique to the pathogen.


Ruslan Medzhitov, 2000

## Damage-associated Molecular Patterns (DAMPs):

Molecules expressed or released that are normally unavailable to the immune system but are released and recognized by immune cells following tissue injury.

Walter L Land, 2003


# Classes of Molecules That Initiate The Adaptive Immune Response – Signal 3



# Classes of Molecules That Promote Continued Adaptive Response – Signal 0 – Environmental Stress

T Helper	Signal 0 Signal 5	Inducer	Transcription Factor	Products
Th1	HMGB1, LPS, ?	IL12	T-bet	IFN $\gamma$
Th2	???	IL4	GATA3	IL4, IL5
Th3	???	IL10, TGF $\beta$	FoxP3	IL10, TGF $\beta$
Th4 [Th17]	↓?? Neut apoptosis	IL23	ROR $\gamma$	IL17, IL6

# HMGB1



*Antagonist to B-Box activity*

*TNF stimulation*

*Stimulates transcription, binds chromatin, shields DNA-cisplatin from exonucleases*

- The High Mobility Group Box-1 Protein, first identified in 1973.

## Intracellular HMGB1

### Co-transcriptional Factor


Structural DNA binding protein  
Stabilizes Nucleosomes  
Transcriptional regulation

## Extracellular HMGB1

### Inflammatory Cytokine

Neutrophil Chemotaxis  
Macrophage activation  
Dendritic cells maturation  
Vascular Leakage  
Acute Lung Injury  
Hepatic Injury  
Multiple Organ Failure

# Immunobiology of HMGB1




Lotze M. T. and Tracey K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* **5**, 331-42.

May 2006

LETTERS

# IL-23 promotes tumour incidence and growth

John L. Langowski<sup>1\*</sup>, Xueqing Zhang<sup>1\*</sup>, Lingling Wu<sup>1</sup>, Jeanine D. Mattson<sup>1</sup>, Taiying Chen<sup>1</sup>, Kathy Smith<sup>1</sup>, Beth Basham<sup>1</sup>, Terrill McClanahan<sup>1</sup>, Robert A. Kastelein<sup>1</sup> & Martin Offt<sup>1</sup>



b

Cancer type	Number of paired (tumour and normal) samples	Fold increase in expression Average	Number		P
			>5x	>10x	
Colon	36	15.33	23	17	0.0001
Ovarian	32	9.45	12	4	0.0001
Head and neck	44	3.41	11	4	0.01
Lung	114	3.03	20	8	0.0001
Breast	78	2.86	16	6	0.0001
Stomach	64	2.13	9	3	0.001
Melanoma	89	1.47	5	0	0.0001

c





Figure 1 | Overexpression of IL-23 but not of IL-12 in human cancer.

# Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Jérôme Galon,<sup>1\*</sup> Anne Costes,<sup>1</sup> Fatima Sanchez-Cabo,<sup>2</sup> Amos Kirilovsky,<sup>1</sup> Bernhard Mlecnik,<sup>2</sup> Christine Lagorce-Pagès,<sup>3</sup> Marie Tosolini,<sup>1</sup> Matthieu Camus,<sup>1</sup> Anne Berger,<sup>4</sup> Philippe Wind,<sup>4</sup> Franck Zinzindohoué,<sup>5</sup> Patrick Bruneval,<sup>6</sup> Paul-Henri Cugnenc,<sup>5</sup> Zlatko Trajanoski,<sup>2</sup> Wolf-Herman Fridman,<sup>1,7</sup> Franck Pages<sup>1,7</sup>†

The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.

29 SEPTEMBER 2006 VOL 313 SCIENCE www.sciencemag.org



Tumor histopathology

UICC-TNM Staging system




Tumor infiltrating immune cells

CD3<sub>CT</sub>CD3<sub>IM</sub> evaluation

CD3<sub>CT</sub>CD3<sub>IM</sub> evaluation

plus

CD45RO<sub>CT</sub>CD45RO<sub>IM</sub> evaluation



# Classes of Molecules That Promote Innate Response – Signal 0 – Environmental Stress

Sentinel	Stress	Antigen	Target	Signal 0 Signal 5
NK	Genomic Metabolic	-	MICA, MICB	HMGB1, LPS, ?
NKT	Cell Membrane	Glycolipid	CD1d	???
CD4	Cell membrane	13-20 Peptide	Class II	???
CD8	ER Stress	8-10 Peptide	Class I	↓?? Neut apoptosis


# Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins

Nature. 1999 June 17 399:708-12.



Uta-Maria Ohndorf\*, Mark A. Rould†‡, Qing He\*, Carl O. Pabo† & Stephen J. Lippard\*

\* Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

† Department of Biology and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA





d(GpG) and d(ApG) adducts




# Release of HMGB1 from Melphalan But not Oxaliplatin Treated Cells

---




# Flow Cytometry Intracellular HMGB1/Histone H1

---




# HMGB1 Release Following Immune Mediated Lysis?

---




# HMGB1 Release Following Immune Mediated Lysis?

---





- HMGB1
- Granzymes
- Perforin
- TRAIL
- TNF-α

# HCT-116 cells treated with chemotherapeutic agents




# HMGB1 Release Assessed Within An ELISA




Western blot of supernatant derived from tumor cells incubated with  
chemotherapeutic agents [48 hours].

---




# Intracellular nuclear staining following treatment with melphalan or oxaliplatin (WM2348 melanoma cell line)

---




# Intracellular nuclear staining of HMGB1 diminishes following treatment with cells with LAK activity





# LAK Induces Intracellular HMGB1 Release

---





# Immune Mediated Lysis of Tumor Cells Release HMGB1



Max(T+NP40)=100

Tumor: 451Lu, 4h,  $5 \times 10^6$ /ml E/T=10/1

# Immune Mediated Lysis of Tumor Cells Release HMGB1



# Apoptosis and Necrosis

---

At The Event Horizon

**A** ← → **N**



# Conclusions 1: Necrosis and Apoptosis and HMGB1

---

- DAMPs and HMGB1 are links between inflammation and necrotic cell death
- Apoptotic cell death causes sequestration of HMGB1 in the nucleus [phosphorylation of Histone 2B] – preliminary Marco Bianchi
- Platination of dsDNA causes sequestration of HMGB1 in the nucleus [dGpG and dGpA]
- Treatment of cancer [and arthritis] with platinum may succeed because of their ability to sequester HMGB1

# Conclusions 2

---

- HMGB1 is indeed a pleiotropic endokine – an endogenous danger signal promoting DC maturation and found in the serum of acute and chronic inflammatory states
- HMGB1 synergizes with other cytokines in the mouse and man to promote **acute** immune reactivity [?Schlepping or Chaperoning]
- HMGB1 in **chronic** inflammation may promote PDC suppression, promoting healing
- Targeting HMGB1 with antibodies or soluble receptors may represent important strategies for treatment of microbial and inflammatory diseases

# Contributors

---

- Herb Zeh/Dave Bartlett/Pawel Kalinski/Zhong Shen Guo/Eric Dong/Petar Popovic/Nicole Schapiro
- Sanjiv Agarwala/John Kirkwood/Howard Edington/ Walter Storkus/Hassane Zarour/Lisa Butterfield
- Shaiv Dave, Scott Plevy
  
- Jukka Vakkila/Lina Lu/Mitchell Fink/Tim Billiar
- Richard DeMarco/David Montag/Norimasa Ito/Ramin Lotfi/Katie Horvath/Elisa Latorre/Tina Kilgore/Yuan Yu
  
- Anna Rubartelli
- Marco Bianchi
- Kevin Tracey
- Ann Marie Schmidt
- Theresa Ostberg, Helena Harris and Ulf Andersson
- Steven Rosenberg/John Wunderlich